Venture&Growth
Location
Munich, Germany
Edwin de Graaf
Managing Partner
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming...
CatalYm
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in...
Fire1
Irish MedTech company focused on remote monitoring of heart failure patients.
